ABSTRACT
Biallelic PARK2 (Parkin) mutations cause autosomal recessive Parkinson’s (PD); however, the role of monoallelic PARK2 mutations as a risk factor for PD remains unclear. We investigated the role of single heterozygous PARK2 mutations in three large independent case-control cohorts totalling 10,858 PD cases and 8,328 controls. Overall, after exclusion of biallelic carriers, single PARK2 mutations were more common in PD than controls conferring a >1.5-fold increase in risk of PD (P=0.035), with meta-analysis (19,574 PD cases and 468,488 controls) confirming increased risk (OR=1.65, P=3.69E-07). Carriers were shown to have significantly younger ages at onset compared to non-carriers (NeuroX: 56.4 vs. 61.4 years; Exome: 38.5 vs. 43.1 years). Stratifying by mutation type, we provide preliminary evidence for a more pathogenic risk profile for single PARK2 copy number variant (CNV) carriers compared to single nucleotide variant carriers. Studies that did not assess biallelic PARK2 mutations or consist of predominantly early-onset cases may be biasing these estimates, and removal of these resulted in a loss of association (OR=1.23, P=0.614; n=4). Importantly, when we looked for additional CNVs in 30% of PD cases with apparent monoallellic PARK2 mutations we found that 44% had biallelic mutations suggesting that previous estimates may be influenced by cryptic biallelic mutation status. While this study supports the association of single PARK2 mutations with PD, it highlights confounding effects therefore caution is needed when interpreting current risk estimates. Together, we demonstrate that comprehensive assessment of biallelic mutation status is essential when elucidating PD risk associated with monoallelic PARK2 mutations.
Competing Interest Statement
H.R.M reports grants from Medical Research Council UK, grants from Wellcome Trust, grants from Parkinson's UK, grants from Ipsen Fund, during the conduct of the study; grants from Motor Neuron Disease Association, grants from Welsh Assembly Government, personal fees from Teva, personal fees from Abbvie, personal fees from Teva, personal fees from UCB, personal fees from Boerhinger-Ingelheim, personal fees from GSK, outside the submitted work. D.K. is the Founder and Scientific Advisory Board Chair of Lysosomal Therapeutics Inc. D.K. serves on the scientific advisory boards of The Silverstein Foundation, Intellia Therapeutics, and Prevail Therapeutics and is a Venture Partner at OrbiMed.
Funding Statement
Please see supplementary data
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As analyses utitlize secondary analyses of suitably anonymized datasets, they do not require ethics committee review. The respective ethical committees for medical research approved involvement in genetic studies and all participants gave written informed consent in the original publications for the datasets used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
For publicly available datasets, the data are available through application at the relevant sites.
ABBREVIATIONS
- %
- Percent
- AAO
- Age at onset
- AR
- Autosomal recessive
- c.
- coding DNA reference sequence
- C1-4
- Principal component 1 to 4
- CI
- Confidence interval
- CNV
- Copy number variant
- Coeff
- β-Coefficient
- dbGaP
- Database of Genotypes and Phenotypes
- DNA
- Deoxyribonucleic acid
- EGA
- European Genome-phenome Archive
- EOPD
- Early-onset Parkinson’s
- FBXO7
- F-box protein 7
- Freq
- Frequency
- I2
- Proportion of total variation caused by heterogeneity
- IPDGC
- International Parkinson’s Disease Genomics Consortium
- LRRK2
- Leucine-rich repeat kinase 2
- MLPA
- Multiplex ligation-dependent probe amplification
- MRC-Holland
- Microbiology Research Centre Holland
- N
- Number
- NM_*
- Messenger RNA sequence identifier
- OMIM
- Online Mendelian Inheritance in Man
- OR
- Odds ratio
- P
- P-value
- p.
- protein reference sequence
- PARK2
- Parkin
- PARK7
- Parkinsonism associated deglycase or DJ-1
- PD
- Parkinson’s
- PD-Monoallelic
- Parkinson’s cases harbouring a single heterozygous PARK2 mutation
- Phet
- Cochran’s Q-statistic test for heterogeneity P-value
- PINK1
- PTEN-Induced putative kinase 1
- Plog
- Logistic regression P-value
- PPMI
- Parkinson’s Progression Markers Initiative
- Preg
- Linear regression P-value
- Reseq
- Resequencing
- SNCA
- α-Synuclein
- SNV
- Single nucleotide variant
- VPS35
- Vacuolar protein sorting 35, yeast, homolog of
- vs.
- Versus
